



KENNY C. GUINN
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

PHARMACY AND THERAPEUTICS COMMITTEE

The Division of Health Care Financing and Policy (DHCFP), Pharmacy and Therapeutics Committee, will conduct a public meeting on **July 27, 2006**, beginning at **1:00 p.m.** at the following location:

**Washoe County Administration Complex
Commission Chambers (Building A)
1001 E. 9th Street
Reno, Nevada 89512**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Pat Manning at: 775-684-3678 or email pmanning@dhcfp.state.nv.us in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment is limited to 3 minutes per individual, organization, or agency, but may be extended at the discretion of the Chairperson.

Agenda

- I. Call to Order and Roll Call
- II. *Review and Approval of April 27, 2006 Minutes
- III. Overview of Preferred Drug List Review Process by Chairperson
- IV. Public Comment
- V. Antibiotics: Cephalosporins 2nd Generation
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VI. Antibiotics: Macrolides
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy

1100 E. William Street, Suite 102, Carson City, Nevada 89701
(775) 684-3600

2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XIII. Ophthalmic Antihistamines
- A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XIV. Respiratory: Beta-Adrenergic Agents, Short-Acting Inhaled
- A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XV. Respiratory: Glucocorticoids, Inhalers
- A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XVI. Respiratory: Glucocorticoids, Nasal
- A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XVII. Drug Classes without Proposed Changes
- A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy without Changes
 1. Analgesics: Long Acting Narcotics
 2. Antibiotics: Cephalosporins 3rd Generation
 3. Antibiotics: Quinolones 2nd Generation
 4. Antibiotics: Quinolones 3rd Generation
 5. Antidepressants: Novel
 6. Antidepressants: SSRIs
 7. Antihistamines: 2nd Generation
 8. Bone Ossification Agents: Biphosphonates
 9. Cardiovascular: Ace Inhibitors & Diuretic Combinations

- E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- VII. Antiemetics: Oral, 5-HT3s
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- VIII. Antifungals: Onychomycosis Agents
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- IX. Anti-Migraine Agents: Triptans
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- X. Central Nervous System: Sedative Hypnotics
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XI. Hepatitis C Agents
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XII. Herpetic Antiviral Agents
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class

10. Cardiovascular: Angiotensins II Receptor Blockers & Diuretic Combination
11. Cardiovascular: Beta Blockers
12. Cardiovascular: Calcium Channel Blockers & ACEI Combinations
13. Cardiovascular: Lipotropics
14. Central Nervous System: ADHD/Stimulants/Non-Stimulants
15. Gastrointestinal Agents: H2RAs
16. Gastrointestinal Agents: PPIs
17. Immunomodulators – Injectable
18. Leukotriene Modifiers
19. Nasal Calcitonins
20. Ophthalmic Glaucoma Agents
21. Ophthalmic Quinolones
22. Respiratory: Anticholinergic Agents, Inhaled
23. Respiratory Agents: Beta-Adrenergic Agents, Long-Acting Inhaled
- B. Public Comment
- C. * Committee Discussion and Approval of Drug Classes without changes for the PDL

XVIII. Review of Next Meeting Location, Date, and Time

XIX. Public Comment

XX. *Adjournment

*** Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcfp.state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.